

# Allan W Cripps

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6585489/publications.pdf>

Version: 2024-02-01

140  
papers

5,421  
citations

87888

38  
h-index

91884

69  
g-index

143  
all docs

143  
docs citations

143  
times ranked

6352  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity, inflammation, and the gut microbiota. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 207-215.	11.4	617
2	Otitis media. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16063.	30.5	332
3	Non-typeable <i>Haemophilus influenzae</i> , an under-recognised pathogen. <i>Lancet Infectious Diseases</i> , 2014, 14, 1281-1292.	9.1	277
4	C-reactive protein: A critical review. <i>Pathology</i> , 1991, 23, 118-124.	0.6	261
5	Salivary IgA levels and infection risk in elite swimmers. <i>Medicine and Science in Sports and Exercise</i> , 1999, 31, 67-73.	0.4	251
6	Nontypeable <i>Haemophilus influenzae</i> : Pathogenesis and Prevention. <i>Microbiology and Molecular Biology Reviews</i> , 1998, 62, 294-308.	6.6	207
7	Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0150949.	2.5	184
8	Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. <i>Clinical Nutrition</i> , 2014, 33, 581-587.	5.0	125
9	Enteropathogens and Chronic Illness in Returning Travelers. <i>New England Journal of Medicine</i> , 2013, 368, 1817-1825.	27.0	120
10	ORAL IMMUNISATION WITH KILLED HAEMOPHILUS INFLUENZAE FOR PROTECTION AGAINST ACUTE BRONCHITIS IN CHRONIC OBSTRUCTIVE LUNG DISEASE. <i>Lancet</i> , 1985, 326, 1395-1397.	13.7	97
11	The Immuno-evasive Activities of <i>Pseudomonas aeruginosa</i> : Relevance for Cystic Fibrosis. <i>The American Review of Respiratory Disease</i> , 1993, 148, 793-805.	2.9	90
12	Microbial Pattern Recognition Receptors Mediate M-Cell Uptake of a Gram-Negative Bacterium. <i>Infection and Immunity</i> , 2006, 74, 625-631.	2.2	90
13	Innate Transcriptional Networks Activated in Bladder in Response to Uropathogenic <i>Escherichia coli</i> Drive Diverse Biological Pathways and Rapid Synthesis of IL-10 for Defense against Bacterial Urinary Tract Infection. <i>Journal of Immunology</i> , 2012, 188, 781-792.	0.8	87
14	Probiotics supplementation for athletes – Clinical and physiological effects. <i>European Journal of Sport Science</i> , 2015, 15, 63-72.	2.7	87
15	An Animal Model Demonstration of Enhanced Clearance of Nontypeable <i>Haemophilus influenzae</i> from the Respiratory Tract after Antigen Stimulation of Gut-associated Lymphoid Tissue. <i>The American Review of Respiratory Disease</i> , 1989, 140, 311-316.	2.9	82
16	Lyme arthritis in the Hunter Valley. <i>Medical Journal of Australia</i> , 1982, 1, 139-139.	1.7	78
17	Modifiers of the human mucosal immune system. <i>Immunology and Cell Biology</i> , 1995, 73, 397-404.	2.3	73
18	Bacterial ghosts as adjuvant particles. <i>Expert Review of Vaccines</i> , 2007, 6, 241-253.	4.4	71

#	ARTICLE	IF	CITATIONS
19	Otitis media: viruses, bacteria, biofilms and vaccines. Medical Journal of Australia, 2009, 191, S44-9.	1.7	67
20	Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents. Frontiers in Pharmacology, 2019, 10, 294.	3.5	65
21	Vaccination against respiratory <i>Pseudomonas aeruginosa</i> infection. Human Vaccines and Immunotherapeutics, 2015, 11, 14-20.	3.3	62
22	Bacterial otitis media: a vaccine preventable disease?. Vaccine, 2005, 23, 2304-2310.	3.8	60
23	Reduction in the Incidence of Acute Bronchitis by an Oral <i>Haemophilus influenzae</i> Vaccine in Patients with Chronic Bronchitis in the Highlands of Papua New Guinea. The American Review of Respiratory Disease, 1991, 144, 324-330.	2.9	59
24	Pathogenesis of Streptococcus urinary tract infection depends on bacterial strain and $\beta$ -hemolysin/cytolysin that mediates cytotoxicity, cytokine synthesis, inflammation and virulence. Scientific Reports, 2016, 6, 29000.	3.3	59
25	Upper Respiratory Symptoms, Gut Health and Mucosal Immunity in Athletes. Sports Medicine, 2018, 48, 65-77.	6.5	59
26	Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5 Fimbrin-Derived Immunogens To Induce Clearance of Nontypeable <i>Haemophilus influenzae</i> from the Rat Middle Ear and Lungs as Well as from the Chinchilla Middle Ear and Nasopharynx. Infection and Immunity, 2003, 71, 4691-4699.	2.2	55
27	Potential of a Novel Protein, OMP26, from Nontypeable <i>Haemophilus influenzae</i> To Enhance Pulmonary Clearance in a Rat Model. Infection and Immunity, 1998, 66, 2272-2278.	2.2	54
28	Prospects for a vaccine against otitis media. Expert Review of Vaccines, 2006, 5, 517-534.	4.4	50
29	Validation and quantitation of an in vitro M-cell model. Biochemical and Biophysical Research Communications, 2002, 299, 377-383.	2.1	46
30	Genome-Wide Mapping of Cystitis Due to <i>Streptococcus agalactiae</i> and <i>Escherichia coli</i> in Mice Identifies a Unique Bladder Transcriptome That Signifies Pathogen-Specific Antimicrobial Defense against Urinary Tract Infection. Infection and Immunity, 2012, 80, 3145-3160.	2.2	46
31	Pulmonary immunity to <i>Pseudomonas aeruginosa</i> . Immunology and Cell Biology, 1995, 73, 418-424.	2.3	45
32	Development of mucosal immunity in the first year of life and relationship to sudden infant death syndrome. FEMS Immunology and Medical Microbiology, 2004, 42, 21-33.	2.7	44
33	Nontypeable <i>Haemophilus influenzae</i> and chronic obstructive pulmonary disease: a review for clinicians. Critical Reviews in Microbiology, 2018, 44, 125-142.	6.1	44
34	Safety and Immunogenicity of an Oral Inactivated Whole-Cell <i>Pseudomonas aeruginosa</i> Vaccine Administered to Healthy Human Subjects. Infection and Immunity, 2006, 74, 968-974.	2.2	43
35	The incidence of <i>Streptococcus pneumoniae</i> otitis media is affected by the polymicrobial environment particularly <i>Moraxella catarrhalis</i> in a mouse nasal colonisation model. Microbes and Infection, 2009, 11, 545-553.	1.9	43
36	Gut Balance, a synbiotic supplement, increases fecal <i>Lactobacillus paracasei</i> but has little effect on immunity in healthy physically active individuals. Gut Microbes, 2012, 3, 221-227.	9.8	43

#	ARTICLE	IF	CITATIONS
37	Urinary tract infection of mice to model human disease: Practicalities, implications and limitations. <i>Critical Reviews in Microbiology</i> , 2016, 42, 1-20.	6.1	43
38	Mucosal immunization: A realistic alternative. <i>Hum Vaccin</i> , 2010, 6, 978-1006.	2.4	42
39	Mediators, Receptors, and Signalling Pathways in the Anti-Inflammatory and Antihyperalgesic Effects of Acupuncture. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-10.	1.2	41
40	New strategies for cancer gene therapy: Progress and opportunities. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 108-114.	1.9	40
41	Early pregnancy factor: its role in mammalian reproduction—research review. <i>Fertility and Sterility</i> , 1981, 35, 397-402.	1.0	37
42	Protection against recurrent acute bronchitis after oral immunization with killed <i>Haemophilus influenzae</i> . <i>Medical Journal of Australia</i> , 1990, 152, 413-416.	1.7	37
43	Activation of the Neutrophil Bactericidal Activity for Nontypable <i>Haemophilus influenzae</i> by Tumor Necrosis Factor and Lymphotoxin. <i>Pediatric Research</i> , 1995, 37, 155-159.	2.3	35
44	Mucosal Immune Response in a Case of Sudden Infant Death Syndrome. <i>Pediatric Research</i> , 1993, 33, 554-556.	2.3	34
45	DETECTION OF AN IMMUNOSUPPRESSIVE FACTOR IN HUMAN PREIMPLANTATION EMBRYO CULTURES. <i>Medical Journal of Australia</i> , 1981, 1, 78-79.	1.7	33
46	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Review of Vaccines</i> , 2021, 20, 243-256.	4.4	33
47	Immunization with Recombinant Transferrin Binding Protein B Enhances Clearance of Nontypeable <i>Haemophilus influenzae</i> from the Rat Lung. <i>Infection and Immunity</i> , 1999, 67, 2138-2144.	2.2	33
48	Bacterial otitis media: Current vaccine development strategies. <i>Immunology and Cell Biology</i> , 2003, 81, 46-51.	2.3	32
49	Immunity, immunopathology, and human vaccine development against sexually transmitted <i>Chlamydia trachomatis</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2664-2673.	3.3	30
50	Introduction: Acute Respiratory Tract Infections—The Forgotten Pandemic. <i>Clinical Infectious Diseases</i> , 1999, 28, 189-191.	5.8	29
51	Enterocyte and M-Cell Transport of Native and Heat-Denatured Bovine $\beta$ -Lactoglobulin: Significance of Heat Denaturation. <i>Journal of Agricultural and Food Chemistry</i> , 2006, 54, 1500-1507.	5.2	28
52	Measurement of lysozyme by an enzyme-linked immunosorbent assay. <i>Journal of Immunological Methods</i> , 1992, 146, 55-61.	1.4	26
53	Effect of acupuncture on house dust mite specific IgE, substance P, and symptoms in persistent allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 497-505.	1.0	25
54	Ontogeny of the Mucosal Immune Response in Children. <i>Advances in Experimental Medicine and Biology</i> , 1991, 310, 87-92.	1.6	25

#	ARTICLE	IF	CITATIONS
55	HIV epidemic in men who have sex with men in Philippines. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 472-473.	9.1	24
56	Mucosal and systemic antibody responses to potential <i>Pseudomonas aeruginosa</i> vaccine protein antigens in young children with cystic fibrosis following colonization and infection. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 506-514.	3.3	24
57	The <i>Streptococcus agalactiae</i> virulence regulator CovR affects the pathogenesis of urinary tract infection. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw589.	4.0	24
58	Discovery and Characterization of Human-Urine Utilization by Asymptomatic-Bacteriuria-Causing <i>Streptococcus agalactiae</i> . <i>Infection and Immunity</i> , 2016, 84, 307-319.	2.2	24
59	The Gut Microbiome of Adults with Allergic Rhinitis Is Characterised by Reduced Diversity and an Altered Abundance of Key Microbial Taxa Compared to Controls. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 94-105.	2.1	24
60	An alteration in the host-parasite relationship in subjects with chronic bronchitis prone to recurrent episodes of acute bronchitis. <i>Immunology and Cell Biology</i> , 1994, 72, 143-151.	2.3	22
61	Characterization of a Novel Porin Protein from <i>Moraxella catarrhalis</i> and Identification of an Immunodominant Surface Loop. <i>Journal of Bacteriology</i> , 2005, 187, 6528-6535.	2.2	22
62	Nontypeable <i>Haemophilus influenzae</i> : challenges in developing a vaccine. <i>Journal of Biotechnology</i> , 1999, 73, 103-108.	3.8	19
63	Specific Protection against Acute Bronchitis Associated with Nontypeable <i>Haemophilus influenzae</i> . <i>Journal of Infectious Diseases</i> , 1992, 165, S194-S195.	4.0	18
64	Mucosal immunization against respiratory bacterial pathogens. <i>Expert Review of Vaccines</i> , 2003, 2, 551-560.	4.4	18
65	CD8 <sup>+</sup> T Cells Have an Essential Role in Pulmonary Clearance of Nontypeable <i>Haemophilus influenzae</i> following Mucosal Immunization. <i>Infection and Immunity</i> , 2001, 69, 2636-2642.	2.2	17
66	Acute on chronic bronchitis: A model of mucosal immunology. <i>Immunology and Cell Biology</i> , 1995, 73, 414-417.	2.3	15
67	A P5 Peptide That Is Homologous to Peptide 10 of OprF from <i>Pseudomonas aeruginosa</i> Enhances Clearance of Nontypeable <i>Haemophilus influenzae</i> from Acutely Infected Rat Lung in the Absence of Detectable Peptide-Specific Antibody. <i>Infection and Immunity</i> , 2000, 68, 377-381.	2.2	15
68	Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. <i>Journal of Biotechnology</i> , 2000, 83, 85-90.	3.8	15
69	A Method for the Purification and Refolding of a Recombinant Form of the Nontypeable <i>Haemophilus influenzae</i> P5 Outer Membrane Protein Fused to Polyhistidine. <i>Protein Expression and Purification</i> , 1999, 15, 1-7.	1.3	14
70	<i>Moraxella catarrhalis</i> M35 Is a General Porin That Is Important for Growth under Nutrient-Limiting Conditions and in the Nasopharynxes of Mice. <i>Journal of Bacteriology</i> , 2008, 190, 7994-8002.	2.2	14
71	Characteristics of the immunological response in the clearance of non-typeable <i>Haemophilus influenzae</i> from the lung. <i>Immunology and Cell Biology</i> , 1998, 76, 323-331.	2.3	13
72	Kinetics of inflammatory cytokines in the clearance of non-typeable <i>Haemophilus influenzae</i> from the lung. <i>Immunology and Cell Biology</i> , 1998, 76, 556-559.	2.3	13

#	ARTICLE	IF	CITATIONS
73	A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. <i>Journal of Alternative and Complementary Medicine</i> , 2018, 24, 833-840.	2.1	13
74	Fucoidan Supplementation Restores Fecal Lysozyme Concentrations in High-Performance Athletes: A Pilot Study. <i>Marine Drugs</i> , 2020, 18, 412.	4.6	13
75	Probiotics, Anticipation Stress, and the Acute Immune Response to Night Shift. <i>Frontiers in Immunology</i> , 2020, 11, 599547.	4.8	13
76	RESTRICTIONS ON MUCOSAL B-LYMPHOCYTE FUNCTION IN MAN. <i>Annals of the New York Academy of Sciences</i> , 1983, 409, 745-750.	3.8	11
77	Challenges for the development of vaccines against <i>Haemophilus influenzae</i> and <i>Neisseria meningitidis</i> . <i>Current Opinion in Immunology</i> , 2002, 14, 553-557.	5.5	11
78	Pneumococcal vaccination in developing countries. <i>Lancet, The</i> , 2006, 368, 644.	13.7	11
79	Optimisation of Oral Immunization Through Receptor-Mediated Targeting of M Cells. <i>Hum Vaccin</i> , 2007, 3, 220-223.	2.4	11
80	Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1885-1893.	3.3	11
81	Do Australian immunoglobulin products meet international measles antibody titer standards?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 607-612.	3.3	11
82	Non-typeable <i>Haemophilus Influenzae</i> detection in the lower airways of patients with lung cancer and chronic obstructive pulmonary disease. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 11.	1.5	11
83	The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-12.	3.3	11
84	Protection against non-typable <i>Haemophilus influenzae</i> following sensitization of gut associated lymphoid tissue: Role of specific antibody and phagocytes. <i>Immunology and Cell Biology</i> , 1995, 73, 258-265.	2.3	10
85	Enteropathogens and Chronic Illness in Returning Travelers. <i>New England Journal of Medicine</i> , 2013, 369, 783-784.	27.0	10
86	Supplementation with a single and double strain probiotic on the innate immune system for respiratory illness. <i>E-SPEN Journal</i> , 2014, 9, e178-e184.	0.5	10
87	Probiotics and Allergic Rhinitis: A Simon Two-Stage Design to Determine Effectiveness. <i>Journal of Alternative and Complementary Medicine</i> , 2016, 22, 1007-1012.	2.1	10
88	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Review of Vaccines</i> , 2021, 20, 257-267.	4.4	10
89	Developmental Profiles of Mucosal Immunity in Pre-school Children. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-10.	3.3	9
90	<i>Haemophilus influenzae</i> and smoking-related obstructive airways disease. <i>International Journal of COPD</i> , 2011, 6, 345.	2.3	9

#	ARTICLE	IF	CITATIONS
91	Are vaccination models suitable to determine whether probiotics have beneficial health effects in the general population?. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 621-624.	3.3	9
92	Distinct Gene Expression Patterns between Nasal Mucosal Cells and Blood Collected from Allergic Rhinitis Sufferers. <i>International Archives of Allergy and Immunology</i> , 2018, 177, 29-34.	2.1	9
93	Characterization of the Gene Encoding a 26-Kilodalton Protein (OMP26) from Nontypeable <i>Haemophilus influenzae</i> and Immune Responses to the Recombinant Protein. <i>Infection and Immunity</i> , 1999, 67, 1935-1942.	2.2	9
94	Detection of Antibody against <i>Helicobacter pylori</i> in the Saliva of Patients with Dyspepsia. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 1994, 8, 408-412.	1.7	8
95	An assessment of mucosal immunisation in protection against <i>Streptococcus equi</i> (â€”Stranglesâ€™) infections in horses. <i>Veterinary Immunology and Immunopathology</i> , 1995, 48, 139-154.	1.2	8
96	Towards a Protein Vaccine for Nontypeable <i>Haemophilus influenzae</i> . <i>Clinical Infectious Diseases</i> , 1999, 28, 238-238.	5.8	8
97	Mucosal Immunization with the <i>Moraxella Catarrhalis</i> Porin M35 Induces Enhanced Bacterial Clearance from the Lung: A Possible Role for Opsonophagocytosis. <i>Frontiers in Immunology</i> , 2011, 2, 13.	4.8	8
98	Ontogeny of Mucosal Immunity and Aging. , 2015, , 161-185.		8
99	The relationship between undernutrition and humoral immune status in children with pneumonia in Papua New Guinea. <i>Papua and New Guinea Medical Journal</i> , 2008, 51, 120-30.	1.0	8
100	Probiotics and Immune Response to Exercise. <i>American Journal of Lifestyle Medicine</i> , 2013, 7, 51-59.	1.9	7
101	Vaccination for the control of childhood bacterial pneumonia â€™ <i>Haemophilus influenzae</i> type b and pneumococcal vaccines. <i>Pneumonia (Nathan Qld )</i> , 2013, 2, 2-15.	6.1	7
102	Oral supplementation with bovine whey-derived Ig-rich fraction and lactoferrin improves SCORAD and DLQI in atopic dermatitis. <i>Journal of Dermatological Science</i> , 2017, 85, 143-146.	1.9	7
103	Innate Immunity in the Middle Ear Mucosa. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 764772.	3.9	7
104	Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profiles. <i>Pneumonia (Nathan Qld )</i> , 2016, 8, 15.	6.1	6
105	Paediatric and adult bronchiectasis: Vaccination in prevention and management. <i>Respirology</i> , 2019, 24, 107-114.	2.3	6
106	The impact of the changing pneumococcal national immunisation program among older Australians. <i>Vaccine</i> , 2021, 39, 720-728.	3.8	6
107	Adult allergic rhinitis sufferers have unique nasal mucosal and peripheral blood immune gene expression profiles: A caseâ€™control study. <i>Immunity, Inflammation and Disease</i> , 2021, 10, 78.	2.7	6
108	Nontypeable <i>Haemophilus influenzae</i> and childhood pneumonia. <i>Papua and New Guinea Medical Journal</i> , 2010, 53, 147-50.	1.0	6

#	ARTICLE	IF	CITATIONS
109	Epitope-specific immune recognition of the nontypeable <i>Haemophilus influenzae</i> outer membrane protein 26. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 625-635.	3.3	5
110	An Oral Whole-Cell Killed Nontypeable <i>Haemophilus influenzae</i> Immunotherapeutic For The Prevention Of Acute Exacerbations Of Chronic Airway Disease. <i>International Journal of COPD</i> , 2019, Volume 14, 2423-2431.	2.3	5
111	Differences in Pneumococcal and <i>Haemophilus influenzae</i> Natural Antibody Development in Papua New Guinean Children in the First Year of Life. <i>Frontiers in Immunology</i> , 2021, 12, 725244.	4.8	5
112	Biotyping respiratory <i>Haemophilus</i> species with the microbact system. <i>Pathology</i> , 1988, 20, 253-255.	0.6	5
113	Recovery of <i>Lactobacillus casei</i> strain Shirota (LcS) from faeces with 14 days of fermented milk supplementation in healthy Australian adults. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2019, 28, 734-739.	0.4	5
114	The handling of inhaled antigen within the respiratory tract. <i>Advanced Drug Delivery Reviews</i> , 1990, 5, 63-72.	13.7	4
115	Viral Co-Infection Does Not Reduce the Efficacy of Vaccination against Non-Typeable <i>Haemophilus influenzae</i> Middle Ear Infection in a Rat Model. <i>Orl</i> , 2001, 63, 96-101.	1.1	4
116	Rubella antibodies in Australian immunoglobulin products. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1952-1955.	3.3	4
117	Integrated biomedical data analysis utilizing various types of data for biomarkers identification. , 2017, , .		4
118	Enteroendocrine and adipokine associations with type 2 diabetes: Phenotypic risk scoring approaches. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1357-1364.	2.8	4
119	The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 663-669.	3.3	4
120	A Microassay for Detecting Merozoite Inhibition Suitable for Routine Laboratory use *. <i>American Journal of Tropical Medicine and Hygiene</i> , 1983, 32, 6-10.	1.4	4
121	Welcome to pneumonia.org.au. <i>Pneumonia (Nathan Qld)</i> , 2012, 1, 1-2.	6.1	3
122	Delivering vaccines for the prevention of pneumonia – programmatic and financial issues. <i>Pneumonia (Nathan Qld)</i> , 2013, 2, 16-25.	6.1	3
123	Gene expression profiles in whole blood and associations with metabolic dysregulation in obesity. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 204-213.	1.8	3
124	Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against <i>Moraxella catarrhalis</i> and nontypeable <i>Haemophilus influenzae</i> . <i>Vaccine</i> , 2020, 38, 309-317.	3.8	3
125	Studies on the IgA-independent immunological responses in mice to influenza virus challenge after oral vaccination with irradiated whole virus and an erythrocyte complex. <i>Immunology and Cell Biology</i> , 2000, 78, 149-155.	2.3	2
126	Mucosal immunization for bacterial respiratory infections. <i>Hum Vaccin</i> , 2008, 4, 396-399.	2.4	2

#	ARTICLE	IF	CITATIONS
127	Peripheral blood natural killer (NK) cell function in healthy adults assessed using the target-induced NK loss (TINKL) assay. <i>Journal of Immunological Methods</i> , 2013, 392, 68-70.	1.4	2
128	The gut microbiome and inflammatory profiling in athlete health. <i>Journal of Science and Medicine in Sport</i> , 2017, 20, e81.	1.3	2
129	Effects of short-term supplementation with bovine lactoferrin and/or immunoglobulins on body mass and metabolic measures: a randomised controlled trial. <i>International Journal of Food Sciences and Nutrition</i> , 2017, 68, 219-226.	2.8	2
130	Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. <i>Vaccine</i> , 2019, 37, 3141.	3.8	2
131	Evaluation of a selective medium for the isolation and differentiation of <i>Haemophilus Influenzae</i> and <i>Haemophilus Parainfluenzae</i> from the respiratory tract of chronic bronchitics. <i>Pathology</i> , 1990, 22, 162-164.	0.6	1
132	Combination of Principal Component Analysis and Genetic Algorithm for Microbial Biomarker Identification in Obesity. , 2018, , .		1
133	Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy. <i>Immunity, Inflammation and Disease</i> , 2021, , .	2.7	1
134	Key viral immune genes and pathways identify elite athletes with URS. <i>Exercise Immunology Review</i> , 2020, 26, 56-78.	0.4	1
135	Welcome to pneumonia Volume 2. <i>Pneumonia (Nathan Qld )</i> , 2013, 2, 1-1.	6.1	0
136	Volume 5 Editorâ€™s Forward. <i>Pneumonia (Nathan Qld )</i> , 2014, 5, i-i.	6.1	0
137	Questionnaire validation: Retrospective analysis of clinical data. <i>Clinical Nutrition</i> , 2015, 34, 1283.	5.0	0
138	Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 641-644.	3.3	0
139	The use of normal human immunoglobulin (NHIG) for public health purposes in Queensland 2004-2014 and Australia 2014-2016. <i>Communicable Diseases Intelligence (2018)</i> , 0, 43, .	0.7	0
140	Cancerbiome: Defining a healthy microbiome for therapeutic targeting.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15152-e15152.	1.6	0